achievement & success of bangladesh epi in integrating nuvi · 2019. 2. 26. · bangladesh epi in...
TRANSCRIPT
-
Achievement & Success of
Bangladesh EPI in Integrating NUVI
Dr. Md. Tajul Islam A. Bari
Program Manager
EPI & Surveillance, DGHS
-
EPI Structure of Rural Area
EPI HQ
District District
Upazila
Union
Ward
Stored in
Cold Room
Stored in ILR
Ward Ward
Immunization Site Each site active
once a month
On day of
vaccination
activities
Stored in ILR
or freezer
64 Districts, 482 Upazila, 140,000 Immunization Sites
-
Vaccination site
• 140,000 EPI outreach sites
• 45,000 regular field workers and 21,000 first line supervisors
• PLUS NGO, community workers and volunteers
-
Urban Primary Health Care Service Delivery
Project (UPHCSDP)
A PROJECT
OF
MINISTRY OF LOCAL GOVERNMENT, RURAL
DEVELOPMENT & CO-OPERATIVES
Implemented by
1 1 City Corporations & 4 Municipalities
-
Vaccination Schedule
Vaccine Age at Vaccination
BCG At Birth
DPT-HepB-Hib W6, W10, and W14
OPV W6, W10, W14, W38
MR MSD
W38 15m-18m
TT (PW & CBAW) MR
Y15, +M1, +M6, +Y1 and Y1 Y15
-
Vaccine Arrival
-
Activities Performed During NUVI Activity Hep B Hib MR
1. Disease burden study √ √ √
2. Strategy & POA √ √ √
3. EPI Assessment √ Cold Chain
(CC) only
CC
4. Revised record keeping &
reporting forms
√ √ √
5. MLM Training & vaccinator
training
√ √ √
6. Advocacy meetings √ √ √
7. IEC activities √ √ √
8. Regular review meetings at
the upazila & districts
√ √ √
9. Post introduction
assessment
√
-
Vaccination coverage by one yr. age
959495
98 99 99 99
98
95
66
69
72
77
8487
86
8990
6465 69
71
78
81
8385
86
63
56
52
64
71
75 75
7980
2001 2002 2003 2005 2006 2007 2009 2010 2011 2012
Percentage
BCG DPT3/Penta3 Measles Fully Vaccinated
Hep-B
Introduction
Pentavalent
Introduction
Measles follow-up
campaign
Measles
catch-up
campaign
Introduce MR vaccine at
9m and MCV2 at 15m
Source: CES-2011
-
Cold Chain Improvement
-
NUV Introduction
• Well accepted by the service providers & the
community
• Introduction was smooth
• Supply of cold chain & logistics was well planned
• Training of HWs before introduction; provided
opportunity to improve the staff skills ay all level
• Vaccine wastage is minimal
• No major safety concerns
-
18
1
10
5
29
16
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006* 2007 2008 2009 2010 2011 2012 2013
Nu
mb
er
of
Ca
se
sPolio Cases, 1996-2013*
No Wild Polio
*Data as of 24th Feb 2013
No Wild Polio
-
A New Vaccine: 'bivalent oral polio vaccine'
71%
49%
86%
53%
0
10
20
30
40
50
60
70
80
90
100
tOPV bOPV tOPV bOPV
Pro
tec
tio
n a
fte
r 2
do
se
s (
%)
Type 1 polio Type 3 polio
-
Validation of NT Elimination
It was documented in 2008 that Bangladesh already
successfully ELIMINATE NEONATAL TETANUS
from the country
-
Vaccine Preventable Disease Surveillance
NT Cases
152 121 117 98 72
206257
748
390
341336
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Numb
er of
Case
s
Measles Cases in Bangladesh
2660718 788
5625
21892924
6192
9743
4067
25935
3484
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Nu
mb
er
of
Ca
se
s
-
Hib Vaccine Impact Assessment on Meningitis us ing S entinel s ite and Defined P opulationP opulation S urveillanc e around S entinel S ite: Inc idenc e (
-
HBsAG Prevalence
Pre vaccine era vs vaccine era
Before introduction
HBsAG prevalence
1.1% among pre-vaccine
era children (born from
April 1, 2001 to March 31,
2002)
After Introduction
HBsAG prevalence
0% among vaccine era
children (born from Nov 1,
2005 to Oct 31, 2006)
-
Central Cold Chain Improvement
-
Global Recognition For Achievement in Reducing Child Mortality
-
Thank you so much
26